KESTRA MEDICAL TECHNOLOGIES, LTD.
For the period ended Jan 31, 2026. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jan 31, 2026 · Filed Mar 17, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
During the three months ended January 31, 2026, Vaseem Mahboob, our Chief Financial Officer, adopted a “Rule 10b5-1 trading arrangement”, as such term is defined in Item 408(a) of Regulation S-K. Mr. Mahboob's trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, and ourpolicies regarding transactions in our securities.
| Name and Title | Date | Action | Expiration Date | Total Shares Subject to Plan |
|---|---|---|---|---|
| Vaseem Mahboob | November 6, 2025 | Adoption | March 5, 2027 | 130,970 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.